Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis, and polymyositis

Neurology

Volumn 51, Issue 6 SUPPL. 5, 1998, Pages

  Dalakas, Marinos C ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; PLACEBO;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOARCHITECTURE; DERMATOMYOSITIS; DISEASE ASSOCIATION; DRUG MEGADOSE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MUSCLE BIOPSY; MUSCLE STRENGTH; MYOSITIS; POLYMYOSITIS; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; STATISTICAL ANALYSIS;

EID: 0032420363     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.51.6_suppl_5.s37     Document Type: Article

References (30)

1. Dalakas MC. Polymyositis, dermatomyositis, and inclusion-body myositis. N Engl J Med 1991;325:1487-1498.
2. Engel AG, Hohlfeld R, Banker BQ. The polymyositis and dermatomyositis syndrome. In: Engel AG, Franzini-Armstrong C, eds. Myology. New York: McGraw-Hill, 1994:1335-1383.
3. Karpati G, Carpenter S. Pathology of the inflammatory myopathies. In: Mastaglia FL, ed. Bailliere's clinical neurology. London: WB Saunders, 1993:527-556.
4. Dalakas MC. Immunopathogenesis of inflammatory myopathies. Ann Neurol 1995;37:74-86.
5. Dalakas MC. Immunopathogenesis of inflammatory myopathies. In: Antel JP, Birnbaum G, Hartung HP, eds. Clinical neuroimmunology. Cambridge, MA: Blackwell Science, 1998: 374-384.
6. Sivakumar K, Dalakas MC. Inclusion body myositis and myopathies. Curr Opin Neurol 1997;10:413-420.
7. Koffman BM, Sivakumar K, Simonis T, Stroncek D, Dalakas MC. HLA allele distribution distinguishes sporadic inclusion body myositis from hereditary inclusion body myopathies. J Neuroimmunol 1998;84:139-142.
8. Koffman BM, Rugiero M, Dalakas MC. Autoimmune diseases and autoantibodies associated with sporadic inclusion body myositis. Muscle Nerve 1998;21:115-117.
9. Dalakas MC. How to diagnose and treat the inflammatory myopathies. Semin Neurol 1994;14:137-145.
10. Dalakas MC. The treatment of polymyositis, dermatomyositis and inclusion body myositis. In: Johnson RT, Griffin JW, eds. Current therapy in neurology. St. Louis: Mosby Year Book, 1996:407-412.
11. Dalakas MC. Polymyositis, dermatomyositis and inclusion body myositis. In: Kassirer JP, Greene HL, eds. Current therapy in adult medicine. St. Louis: Mosby-Year Book, 1997: 1434-1439.
12. Dalakas MC. Treatment of polymyositis and dermatomyositis. Curr Opin Rheumatol 1989;1:443-449.
13. Miller FW, Leitman SF, Cronin ME, et al. Controlled trial of plasma exchange and leukopheresis in polymyositis and dermatomyositis. N Engl J Med 1992;326:1380-1384.
14. Cherin P, Herson S, Wechsler B, et al. Efficacy of intravenous immunoglobulin therapy in chronic refractory polymyositis and dermatomyositis. An open study with 20 adult patients. Am J Med 1991;91:162-168.
15. Lang B, Laxer RM, Murphy G, Silverman ED, Roitmani CM. Treatment of dermatomyositis with intravenous immunoglobulin. Am J Med 1991;91:169-172.
16. Jan S, Beretta S, Moggio M, Alobbati L, Pellegrini G. High-dose intravenous human immunoglobulin in polymyositis resistant to treatment. J Neurol Neurosurg Psychiatry 1992;55: 60-64.
17. Soueidan SA, Dalakas MC. Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin. Neurology 1993;43:876-879.
18. Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, et al. A controlled trial of high-dose intravenous immunoglobulin infusions as treatment for dermatomyositis. N Engl J Med 1993; 329:1993-2000.
19. Dalakas MC. Intravenous immune globulin for dermatomyositis. N Engl J Med 1994;330:1392-1393.
20. Dalakas MC. Experience with IVIg in the treatment of inflammatory myopathies. In: Kazatchkine M, Morel A, eds. Intravenous immunoglobulin research and therapy. London: Parthenon Publishing, 1996:275-284.
21. Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 1994;94:1729-1735.
22. Dalakas MC. Clinical relevance of IVIg in the modulation of the complement-mediated tissue damage: implications in dermatomyositis, Guillain Barré syndrome and myasthenia gravis. In: Kazatchkine M, Morel A eds. Intravenous immunoglobulin research and therapy. London: Parthenon Publishing, 1996:89-93.
23. Dalakas MC. Mechanism of action of intravenous immunoglobulin and therapeutic considerations in the treatment of autoimmune neurologic diseases. Neurology 1998;51(suppl 5): S2-S8.
24. Dalakas MC, Pezeshkpour GH, Gravell M, Sever JL. Polymyositis in patients with AIDS. JAMA 1986;256:2381-2383.
25. Dalakas MC, Pezeshkpour GH. Neuromuscular diseases associated with human immunodeficiency virus infection. Ann Neurol 1988;23(Suppl):38-48.
26. Cupler EJ, Leon-Monzon M, Miller J, Semino-Mora C, Anderson TL, Dalakas MC. Inclusion body myositis in HIV-1 and HTLV-1 infected patients. Brain 1996;119:1887-1893.
27. Leon-Monzon M, Illa I, Dalakas MC. Polymyositis in patients infected with HTLV-I: the role of the virus in the cause of the disease. Ann Neurol 1994;36:643-649.
28. Amato AA, Barohn RJ, Jackson CE, et al. Inclusion body myositis: treatment with intravenous immunoglobulin. Neurology 1993;43:876-879.
29. Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K. Treatment of inclusion body, myositis with IVIg: a double-blind, placebo-control study. Neurology 1997;48:712-716.
30. Dalakas MC, Sonies B, Koffman B, Spector S, Sivakumar K, Cupler E, Lopez-Devine J. High-dose intravenous immunoglobulin (IVIg) combined with prednisone in the treatment of patients with inclusion-body myositis (IBM): a double blind, randomised controlled trial [Abstract]. Neurology 1997;48:332.